IARC launches VRtuose: VR and music for cancer care

Virtual reality and music tool supports chemotherapy patients

VRtuose project website

VRtuose project website

VRtuose project website was launched by IARC on 22 July 2025, detailing the use of virtual reality combined with music to support patients undergoing chemotherapy, particularly for breast cancer. Developed with Centre Léon Bérard (Lyon) and funded through the Ruban Rose 2023 Quality-of‑Life prize, the initiative evaluates feasibility, acceptability, and tolerability in clinical settings.

 

The Goal

It aims to reduce anxiety, improve treatment adherence, and enhance patient well‑being, with plans to scale across European centres. Conducting this study will provide information about whether the use of VR distraction tools fits the needs of patients with breast cancer who are undergoing chemotherapy and whether it is compatible with clinical practice.

 

👉Read more

#EuCanScreen #CancerScreening #HealthCare #CancerPrevention #BreastCancer #Virtualreality #MusicTherapy

🔗 Please don’t forget to Subscribe to EuCanScreen Newsletter! 💪

Subscribe to our newsletter to get news and updates.

Subscribe to our newsletter to get news and updates.

Logo EU EUCanScreen Vertical

 

Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HADEA). Neither the European Union nor HADEA can be held responsible for them.

tiktok

FaceBook

X

Instagram

YouTube

LinkedIn

email

EUCanScreenLogo t

The general objective of EUCanScreen is to assure sustainable implementation of high-quality screening for breast, cervical and colorectal cancers, as well as implementation of the recently recommended screening programs – for lung, prostate and gastric cancers. EUCanScreen will facilitate the reduction of cancer burden and achieving equity across the EU.

FaceBook

Twitter

Instagram

YouTube

LinkedIn

Logo EU tr

This project has received funding from the European Union’s EU4HEALTH Programme under the Grant Agreement no 101162959

Μετάβαση στο περιεχόμενο